Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab Exposure-Response in Ulcerative Colitis Using Serum Trough Levels
2017-001374-42Phase 4Unknown
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
- Start
- Jul 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of golimumab in autoimmune colitis, sponsored by Guy's and St Thomas' NHS Foundation Trust. Primary endpoints: Golimumab trough levels at weeks 6 and 10 predicting week 14 response and Golimumab trough levels at weeks 6, 10, and 14 predicting response at each time point. Status: unknown.
02
Drugs
golimumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2017-001374-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001374-42.